Last reviewed · How we verify
MenACWY single dose + paracetamol
MenACWY is a conjugate vaccine that stimulates the immune system to produce antibodies against meningococcal serogroups A, C, W, and Y, while paracetamol is co-administered to manage potential fever and discomfort from vaccination.
MenACWY is a conjugate vaccine that stimulates the immune system to produce antibodies against meningococcal serogroups A, C, W, and Y, while paracetamol is co-administered to manage potential fever and discomfort from vaccination. Used for Prevention of meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y.
At a glance
| Generic name | MenACWY single dose + paracetamol |
|---|---|
| Sponsor | University of Oxford |
| Drug class | Conjugate vaccine |
| Target | Meningococcal polysaccharide capsules (serogroups A, C, W, Y) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
MenACWY works by presenting polysaccharide antigens from four meningococcal serogroups conjugated to a protein carrier, triggering both T-cell and B-cell immune responses that generate protective antibodies. Paracetamol is included as a co-medication to reduce post-vaccination fever and systemic symptoms, potentially improving tolerability and compliance in the study population.
Approved indications
- Prevention of meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y
Common side effects
- Injection site pain
- Injection site erythema
- Fever
- Myalgia
- Fatigue
- Headache
Key clinical trials
- A Study of a Candidate COVID-19 Vaccine (COV001) (PHASE1, PHASE2)
- A Study of a Candidate COVID-19 Vaccine (COV003) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |